GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Dynatronics Corp (NAS:DYNT) » Definitions » Debt-to-EBITDA
中文

Dynatronics (Dynatronics) Debt-to-EBITDA

: -3.03 (As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dynatronics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.21 Mil. Dynatronics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.70 Mil. Dynatronics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-2.28 Mil. Dynatronics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -3.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dynatronics's Debt-to-EBITDA or its related term are showing as below:

DYNT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.18   Med: -1.6   Max: 146.37
Current: -2.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of Dynatronics was 146.37. The lowest was -10.18. And the median was -1.60.

DYNT's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs DYNT: -2.03

Dynatronics Debt-to-EBITDA Historical Data

The historical data trend for Dynatronics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynatronics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.32 -8.63 1.33 -1.58 -1.61

Dynatronics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.95 -1.66 -0.70 22.08 -3.03

Competitive Comparison

For the Medical Devices subindustry, Dynatronics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynatronics Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Dynatronics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dynatronics's Debt-to-EBITDA falls into.



Dynatronics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dynatronics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.362 + 4.286) / -3.506
=-1.61

Dynatronics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.212 + 3.697) / -2.284
=-3.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Dynatronics  (NAS:DYNT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Dynatronics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dynatronics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynatronics (Dynatronics) Business Description

Traded in Other Exchanges
N/A
Address
1200 Trapp Road, Eagan, MN, USA, 55121
Dynatronics Corp is a United States-based company that is engaged in designing, manufacturing, and distributing advanced-technology medical devices, therapeutic and medical treatment tables, rehabilitation equipment, custom athletic training treatment tables and equipment, institutional cabinetry as well as other rehabilitation and therapy products and supplies. The company markets and sells its products to physical therapists, chiropractors, athletic trainers, sports medicine practitioners, and other medical professionals and institutions. It offers customers a one-stop-shop for their medical equipment and supply needs, including electrotherapy, therapeutic ultrasound, phototherapy, rehabilitation products, treatment tables, customized training room products, and exercise products.
Executives
Gabriel Ellwein officer: Chief Financial Officer 4782 HIGHCROFT COURT, EAGAN MN 55122
John Anthony Krier director, officer: Chief Executive Officer 319 WEST 50TH SOUTH, MINNEAPOLIS MN 55419
David B Holtz director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Scott Klosterman director
R Scott Ward director 1064 S. CRESTVIEW CIRCLE, SLC VA 84108
Stuart Essig 10 percent owner 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536
Brian Larkin director INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Brian D. Baker officer: Chief Operating Officer C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Provco Ventures 1 Lp 10 percent owner 795 E LANCASTER AVE SUITE 200, VILLANOVA PA 19085
Norman Iii Roegner officer: Chief Financial Officer 1200 TRAPP ROAD, EAGAN MN 55121
Skyler N Black officer: Corporate Controller 1448 E LEXI LN, COTTONWOOD HEIGHTS UT 84093
Keeler Jennifer Bennett Bennett officer: Secretary / General Counsel 8620 STILLWATER BLVD N, LAKE ELMO MN 55042
Daryl Connell officer: Chief Information Officer 932 MINJON DRIVE, APPLE VALLEY MN 55124
Cynthia L. Mchenry officer: VP, Operations 7030 PARK CENTRE DRIVE, COTTONWOOD HEIGHTS UT 84121